Metagenomi, Inc. (NASDAQ:MGX) Receives $16.67 Average Price Target from Analysts

Metagenomi, Inc. (NASDAQ:MGX) has received an average rating of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $16.67.

MGX has been the topic of a number of research analyst reports. HC Wainwright raised their target price on Metagenomi from $7.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, December 10th. Chardan Capital reaffirmed a “buy” rating and issued a $15.00 target price on shares of Metagenomi in a report on Wednesday, November 20th.

Metagenomi Stock Up 7.5 %

MGX opened at $2.85 on Friday. The stock’s 50 day moving average price is $3.01 and its two-hundred day moving average price is $2.86. Metagenomi has a 12-month low of $1.61 and a 12-month high of $12.74.

Institutional Trading of Metagenomi

Several institutional investors have recently modified their holdings of MGX. Rhumbline Advisers acquired a new stake in shares of Metagenomi during the 2nd quarter worth approximately $26,000. XTX Topco Ltd acquired a new stake in Metagenomi in the 2nd quarter valued at $66,000. Novo Holdings A S boosted its stake in Metagenomi by 3.5% in the 2nd quarter. Novo Holdings A S now owns 1,800,000 shares of the company’s stock valued at $7,344,000 after buying an additional 60,825 shares in the last quarter. Green Alpha Advisors LLC acquired a new stake in Metagenomi in the 3rd quarter valued at $69,000. Finally, BNP Paribas Financial Markets boosted its stake in Metagenomi by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock valued at $28,000 after buying an additional 7,256 shares in the last quarter.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.